| CinCor Pharma is a biopharmaceutical company focused on developing its primary clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Co. is developing CIN-107 for the indication of chronic kidney disease and primary aldosteronism. We show 1 historical shares outstanding datapoints in our coverage of CINC's shares outstanding history.|
Understanding the changing numbers of CINC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CINC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CINC by allowing them to research CINC shares outstanding history
as well as any other stock in our coverage universe.